undamentalytics Newsletter
Sign in

PTC Therapeutics, Inc. cash flow statement

In fiscal 2025, PTC Therapeutics, Inc.'s operations generated $711m of cash; it spent $8.9m on capital projects, leaving free cash flow of $702m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−21−48−47−57−124−104−10−28−99−194−251−357−158−10871110
Depreciation and amortisation3322331826324364129237763961
Stock-based pay32819343531334270104110102757589
Capital spending001532371418283228798
Free cash flow−21−48−48−62−127−105−13−35−112−212−280−389−187−1147022
Free cash flow after stock pay−24−50−56−81−161−140−44−68−155−282−383−499−288−189628−87
Shares issued0—13223600011832428——————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ACAD vs PTCTLKFT vs PTCTMDGL vs PTCT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from PTC Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to PTC Therapeutics, Inc.